Jia G, He P, Dai T, Goh D, Wang J, Sun M
Nature. 2025; .
PMID: 40074893
DOI: 10.1038/s41586-025-08668-x.
Suo Y, Song Y, Wang Y, Liu Q, Rodriguez H, Zhou H
Biophys Rep. 2025; 11(1):56-76.
PMID: 40070661
PMC: 11891078.
DOI: 10.52601/bpr.2024.240053.
Zhang X, Zhang T, Wu F, Li Z, Xiao Z, Yu Z
Hepatol Int. 2025; .
PMID: 40063322
DOI: 10.1007/s12072-025-10802-w.
Ma L, Luan Y, Lu L
Cancer Med. 2025; 14(5):e70622.
PMID: 40062730
PMC: 11891933.
DOI: 10.1002/cam4.70622.
Mu X, Pan L, Wang X, Liu C, Li Y, Cai Y
Front Immunol. 2025; 16:1529569.
PMID: 40051627
PMC: 11882567.
DOI: 10.3389/fimmu.2025.1529569.
Benchmarking copy number aberrations inference tools using single-cell multi-omics datasets.
Song M, Ma S, Wang G, Wang Y, Yang Z, Xie B
Brief Bioinform. 2025; 26(2).
PMID: 40037644
PMC: 11879432.
DOI: 10.1093/bib/bbaf076.
Predictive circulating biomarkers of the response to anti-PD-1 immunotherapy in advanced HER2 negative breast cancer.
Wei Y, Ge H, Qi Y, Zeng C, Sun X, Mo H
Clin Transl Med. 2025; 15(3):e70255.
PMID: 40000397
PMC: 11859116.
DOI: 10.1002/ctm2.70255.
Discovery of Endothelial-Monocyte Crosstalk in Ischemic-Reperfusion Injury Following Liver Transplantation Based on Integration of Single-Cell RNA and Transcriptome RNA Sequencing.
Sun C, Li L, Li D, Wang Z
J Cell Mol Med. 2025; 29(4):e70336.
PMID: 39993960
PMC: 11850096.
DOI: 10.1111/jcmm.70336.
Role of CD4 T cells in cancer immunity: a single-cell sequencing exploration of tumor microenvironment.
An Q, Duan L, Wang Y, Wang F, Liu X, Liu C
J Transl Med. 2025; 23(1):179.
PMID: 39953548
PMC: 11829416.
DOI: 10.1186/s12967-025-06167-1.
Molecular landscape of tumor-associated tissue-resident memory T cells in tumor microenvironment of hepatocellular carcinoma.
Park M, Jo H, Kim H, Kim J, Park W, Paik Y
Cell Commun Signal. 2025; 23(1):80.
PMID: 39934824
PMC: 11818299.
DOI: 10.1186/s12964-025-02070-w.
Multi-omics analyses reveal biological and clinical insights in recurrent stage I non-small cell lung cancer.
Wang C, Li J, Chen J, Wang Z, Zhu G, Song L
Nat Commun. 2025; 16(1):1477.
PMID: 39929832
PMC: 11811181.
DOI: 10.1038/s41467-024-55068-2.
Spatial‒temporal heterogeneities of liver cancer and the discovery of the invasive zone.
Yan J, Jiang Z, Zhang S, Yu Q, Lu Y, Miao R
Clin Transl Med. 2025; 15(2):e70224.
PMID: 39924620
PMC: 11807767.
DOI: 10.1002/ctm2.70224.
Pre-immunotherapy alters stereotactic ablative radiotherapy-induced systemic T cell responses in early-stage NSCLC.
Liu C, Chen Y, Li X, Bai Z, Jiang M, Sheng D
Cancer Immunol Immunother. 2025; 74(3):80.
PMID: 39891774
PMC: 11787101.
DOI: 10.1007/s00262-024-03935-8.
Single-cell RNA-seq reveals immune cell heterogeneity and increased Th17 cells in human fibrotic skin diseases.
Deng C, Xu X, Zhang Y, Liu L, Wang X, Chen J
Front Immunol. 2025; 15:1522076.
PMID: 39872534
PMC: 11769821.
DOI: 10.3389/fimmu.2024.1522076.
Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma.
Cheng Y, Chen X, Feng L, Yang Z, Xiao L, Xiang B
Cell Discov. 2025; 11(1):1.
PMID: 39870619
PMC: 11772884.
DOI: 10.1038/s41421-024-00747-z.
Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches.
Eghbali S, Heumann T
Cancers (Basel). 2025; 17(2).
PMID: 39858016
PMC: 11764197.
DOI: 10.3390/cancers17020236.
NK cell exhaustion in Wilson's disease revealed by single-cell RNA sequencing predicts the prognosis of cholecystitis.
Jin Y, Xing J, Dai C, Jin L, Zhang W, Tao Q
Elife. 2025; 13.
PMID: 39854622
PMC: 11684787.
DOI: 10.7554/eLife.98867.
Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression.
Zhou M, Zhou Z, Hu L, Chen S, Meng F, Chen J
J Transl Med. 2025; 23(1):88.
PMID: 39838375
PMC: 11748271.
DOI: 10.1186/s12967-025-06106-0.
Development of a Microvessel Density Gene Signature and Its Application in Precision Medicine.
Kuronishi M, Ozawa Y, Kimura T, Li S, Kato Y
Cancer Res Commun. 2025; 5(3):398-408.
PMID: 39835481
PMC: 11880750.
DOI: 10.1158/2767-9764.CRC-24-0403.
TLR7/8/9 agonists and low-dose cisplatin synergistically promotes tertiary lymphatic structure formation and antitumor immunity.
Wu S, Xiang R, Zhong Y, Zhao S, Zhang Z, Kou Z
NPJ Vaccines. 2025; 10(1):13.
PMID: 39827246
PMC: 11742977.
DOI: 10.1038/s41541-024-01055-z.